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Pancreatic ductal adenocarcinoma is a lethal and late pre-
senting malignancy with dismal survival rates. An estimated 
total of 330,000 people died from this malignancy in 2012. 
Although there have been improvements in diagnostic and 
treatment methods, the survival of late stage pancreatic can-
cer has not shown significant improvement in the past 4 dec-
ades. Multiple treatment approaches are available including 
chemotherapy, radiotherapy, and immunotherapy, but to this 
day surgical resection remains the only curative treatment op-
tion. Ablative techniques use various forms of energy to cause 
local tissue destruction through necrosis or apoptosis. They 
are relevant in pancreatic ductal adenocarcinoma as they are 
a treatment option in non-resectable tumors where their use 
ranges from symptom control to reducing tumor size for resec-
tion. In this narrative review we have grouped and outlined the 
various ablative methods, classifying them into thermal (Radi-
ofrequency ablation, Microwave ablation, High Intensity Fo-
cused Ultrasound ablation, Cryoablation), and non-thermal 
ablative methods (Irreversible Electroporation (NanoKnife®), 
Photodynamic Therapy). This is followed by a description and 
review of the available evidence on survival and complications 
for each of these ablative methods. According to the literature, 
thermal ablative methods appear to be more accessible but are 
implicated with more complications than non thermal abla-
tive methods which show the most promise. 
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Pancreatic ductal adenocarcinoma is the 10th 
most common cancer as well as the 5th most com-
mon cause of death due to cancer in the UK [1]. 
Over the last decade it has been estimated that 
the incidence of pancreatic cancer has increased 
by 8% [1]. Furthermore, for the year 2012 it was 
the cause for 8,662 deaths, translating to roughly 
24 deaths per day. A total of 330,000 people were 
estimated to have died of pancreatic cancer world-
wide in 2012 [1]. Despite improvements in treat-
ment methods, the survival of pancreatic cancer 
has not shown any significant improvement in the 
past 4 decades [1].
Pancreatic ductal adenocarcinoma is a cancer 
with a very poor prognosis, mostly due to its ad-
vanced stage by the time of presentation. For most 
patients, the tumor has already invaded the local 
structures. Patients presenting with local progres-
sion without distal metastasis have an expected 
survival of 6 to 12 months, compared to a surviv-
al of 3 to 6 months for presentation with distal 
metastasis [2,3]. In the UK, only 1% of patients 
survive for more than 10 years, and a bit less than 
3% survive for more than 5 years [1]. Roughly 4 in 
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5 of the patients diagnosed with pancreatic ductal 
carcinoma will not survive for more than a year 
from diagnosis [1]. 
Currently, the standard approach for the 
treatment of locally advanced pancreatic cancer 
includes multidisciplinary teams implementing 
chemotherapy and radiotherapy [4,5]. With the 
recent notable exception of FOLFIRINOX (fluo-
rouracil, leucovorin, irinotecan, and oxaliplatin) 
[5-9], chemotherapy and radiotherapy have had 
very little success in improving survival, or re-
ducing the size of the tumor to render it resect-
able [10,11]. To this day, resection of the tumor 
remains the only curative treatment choice. A 
2012 cohort study demonstrated a 5-year survival 
rate of 18% after surgical resection with curative 
intent. The median survival was found to be 18 
months [2,12].
Due to the delayed presentation of pancreatic 
cancer patients, surgical resection is only an op-
tion for a small proportion of the patients. In the 
US it is found that 80% of the patients are not can-
didates for surgery because of metastatic (50%) or 
locally invading (30%) disease [13]. Similar rates 
are found in the UK where an average of only 
8% of pancreatic cancer patients receive surgical 
resection, although this rate varies significantly 
with the patients’ age [14]. In those aged between 
15 to 54 years, 19% received surgical resection, 
while in those aged 75 to 84 years, only 4% re-
ceived surgical resection [14]. A tumor is consid-
ered non-resectable when there is involvement of 
the superior mesenteric artery, coeliac trunk, or 
portal vein on cross section imaging [2,15,16]. 
Recent years have seen an increased interest 
in the use of ablative therapies for the treatment 
of non-resectable tumors in organs such as the 
liver and kidney [2,5,6,17]. Local ablation tech-
niques apply various different types of energy 
to a tissue for the purpose of inducing tissue de-
struction. Early studies using ablative techniques 
on the pancreas were associated with significant 
morbidity and mortality, however improvements 
in imaging techniques and ablative modalities are 
now commencing to show promising results for 
the surgical management of non-resectable pan-
creatic tumors as well [2,5,6,18].
In this narrative review we aimed to group and 
outline the various ablative methods, followed by 
a description and review of the available evidence 
on their survival rates and complications. Tables 
summarizing the collective evidence of previous 
research articles are also included. 
Methods
The review of the literature focused on keyword 
searches of electronic databases, such as MEDLINE, 
Embase, Cochrane Library, and Google Scholar for arti-
cles dated past the year 2000. Our search terms includ-
ed ‘pancreatic cancer’, ‘pancreas’, ‘ablation’, ‘tumor’, 
‘Locally Advanced’, ‘metastasis’, ‘resection’, ‘radiof-
requency’, ‘Catheter’, ‘Microwave’, ‘photodynamic’, 
‘PDT’, ‘High Intensity Focused Ultrasound’, ‘HIFU’, 
’laser’, ‘Cryoablation’, ‘Irreversible Electroporation’, 
‘Photodynamic Therapy’, in various configurations. 
We selected the relevant case series, prospective and 
retrospective studies, case control studies, narrative 
and systematic reviews, and meta-analyses. Through 
further review of the selected articles and hand-picked 
references, we formulated this narrative review. 
Results
Ablative methods
Ablative methods implement various forms 
of energy which are used to induce tissue destruc-
tion in a specific area of the body. These include 
thermal, electrical, chemical, sound, and light 
energies which are categorized into the larger 
groups of thermal and non-thermal ablation meth-
ods [2,19,20]. Thermal ablative methods include 
radiofrequency ablation (RFA), microwave abla-
tion (MWA), high frequency focused ultrasound 
(HIFU), and cryoablation. Non-thermal ablative 
methods include irreversible electroporation 
(IRE), and photodynamic therapy (PDT). The ra-
tionale behind ablation is that local destruction of 
the tumor cells can lead to deceleration of disease 
progression, which can then potentially translate 
to improved survival for the patients [2,20].
Ablation is a treatment option aimed at pa-
tients who have non-resectable pancreatic cancer. 
It can also be used for patients who cannot toler-
ate the standard chemotherapy and/or radiother-
apy methods. The goal of ablation is to provide 
relief of symptoms such as pain, and down-stag-
ing of the tumor, potentially allowing for a future 
resection of the lesion [2]. 
The major risk of ablation is harm caused to 
adjacent healthy tissues. Being a very delicate or-
gan, and located in a very crowded anatomical re-
gion this is a considerable risk which determines 
the feasibility and difficulty of using the various 
ablation techniques on the pancreas [2,20]. This 
is one of the main reasons that chemical ablation 
methods are not implemented in the pancreas, as 
leakage of these chemical agents into the arterial 
system could prove fatal [2,19].
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Thermal ablative methods
Thermal ablative methods aim to create ex-
tremely high or low temperatures which lead 
to tumor ablation and cell necrosis [2,20]. The 
temperatures required to induce tissue damage 
leading to tumor necrosis have been found to be 
>50⁰C or <-40⁰C [2,20-22]. The ablative techniques 
implemented create these temperatures include 
RFA, MWA, HIFU, and cryoablation [2,20].
Radiofrequency ablation (RFA)
RFA is the most common thermal ablative 
method used for the treatment of solid abdominal 
tumors [23]. Through the use of high-frequency 
alternating current this mode of ablation produc-
es coagulative necrosis of tumor cells by creating 
temperatures above 50⁰C. This is done by inserting 
one or more electrodes inside the tumor [2,20,24]. 
In addition to the thermal ablation, RFA may also 
be responsible for inducing the expression of heat 
shock protein 70, enhancing a patient’s anti-tu-
mor immunity [23,25].
The reported mortality and morbidity of RFA 
in the management of locally advanced pancreatic 
cancer has been summarized in a recent systemat-
ic review [20] which included datasets from prior 
reviews [26]. According to Rombouts et al. review 
of 7 studies accounting for a total 342 patients, 
the morbidity rate ranged from 4-22%, while the 
mortality rate from 0-11% [20] (Table 1). It was 
also noticed that both the highest mortality and 
morbidity range were found in the earlier study 
published in 2000 [20,27]. Long term survival af-
ter RFA, reported in 5 studies, showed a median 
range from 5 to 25 months [20]. The largest of 
those studies, accounting for 100 patients, showed 
a 20-month median survival [28] and the second 
largest, with 57 patients showed a 19-month sur-
vival [29] (Table 1). Pain scores have been shown 
Table 1. Summary of articles reporting on median survival of thermal ablative techniques in unresectable pancreat-
ic cancer
Article authors Publication year Ablative technique Number of patients Median survival (months)
Cantore et al. [80] 2012 RFA 107 25.6 
Frigerio et al. [29] 2013 RFA 57 19.0
Girelli et al. [28] 2013 RFA 100 20.0 
Matsui et al. [27] 2000 RFA 9 5.0 
Spiliotis et al. [21] 2007 RFA 8 13–19 
Lygidakis et al. [33] 2007 MWA 15 22 
Wu et al. [41] 2005 HIFU 8 11.2 
Xiong et al. [42] 2009 HIFU 89 26.0 (stage II)
11.2 (stage III) 5.4 (stage IV)
Zhao et al. [43] 2010 HIFU 37 12.6 
Sung et al. [82] 2011 HIFU 46 12.4 
Wang et al. [83] 2011 HIFU 40 10 (stage III) 
6 (stage IV).
Lee et al. [84] 2011 HIFU 12 10.3 mo
Li et al. [85] 2012 HIFU 25 10 
Gao et al. [86] 2013 HIFU 39 11 
Li et al. [57] 2004 Cryoablation 44 14 
Wu et al. [61] 2005 Cryoablation 15 13.4 
Xu et al. [60] 2008 Cryoablation 38 12 
Xu et al. [59] 2008 Cryoablation 49 16.2 
Li et al. [56] 2011 Cryoablation, with 
palliative bypass 
surgery
68 30 (6-49) 
Xu et al. [55] 2013 Cryoablation 59 8.4 
Niu et al. [54] 2013 Cryoablation 36 Cryoablation 
alone;
31 with chemothe-
rapy
7 
13 
For abbreviations see text
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to decrease in 50 and 69% of patients postopera-
tively [18,20,30]
The complications of RFA include thermal 
vein damage and duodenal damage which ap-
peared to occur at higher frequency when a high-
er target tissue temperature of 105⁰C was used, 
when compared to a 90⁰C target [18].  When RFA 
margin threshold of 5mm from the tip to the ma-
jor peri-pancreatic vessels was used, pancreatic 
fistula, vessel damage, and gastrointestinal bleed-
ing after portal vein thrombosis were found to be 
common complications [30]. Use of margins wid-
er than 5mm have been suggested, although no 
safe distance has been established yet [2,18,30]. 
Intraoperative cooling methods, such as continu-
ous irrigation with cool saline, have been reported 
to decrease risk of damage to nearby tissue [30], 
and endoscopically inserted cooling devices may 
also be used in the duodenum to prevent thermal 
damage [26]. 
Microwave ablation (MWA)
MWA achieves frequencies ranging from 900 
to 2450 MHz which cause oscillation of polar mol-
ecules such as water, resulting in the creation of 
heat by frictional agitation. As the charge on the 
water molecules oscillates up to 5 billion times 
a second, the high temperatures required for in-
duction of coagulative necrosis are reached, and 
ablation is achieved [2,20,31,32]. The probes used 
in microwave ablation are very similar to the ones 
used in RFA and are referred to as “antennas” [2].
MWA is a less studied technique with only 
few articles available reporting mortality, morbid-
ity, and quality of life improvements. In a series of 
15 patients treated with MWA, the longest surviv-
al reported was 22 months [33] (Table 1). 
Minor complications were seen in 40% of the 
patients, including mild pancreatitis, asympto-
matic hyperamylasemia, pancreatic ascites, and 
minor bleeding [33]. Pseudocyst development was 
another complication described in a case report 
[34]. Advantages of MWA are less procedural pain 
with faster ablation times, possibility of greater 
intra-tumoral target temperature without heat-
sink effect when closer to vessels, higher ablation 
volumes, reproducible ablation zones, and abili-
ty to simultaneously use multiple applicators 
[31,32,35,36]. A limitation of MWA is the drop 
shape of the necrotic area formed, however new 
advances in the technology are expected to pro-
duce more spherical ablation zones [2].
High intensity focused ultrasound (HIFU)
HIFU causes tissue damage and death by two 
known mechanisms, heat and cavitation [37]. Heat 
production is achieved by the ability of tumor tis-
sue to absorb focused acoustic energy and trans-
form it into thermal energy [2,20,38]. Cavitation 
is an effect of ultrasound beams which leads to 
oscillating compression and rarefaction of molec-
ular structures. The molecular mechanical stress-
es created by these vibrations result in the gener-
ation of thermal energy and temperatures as high 
as 5000 K [37,39]. The high temperatures induce 
coagulative necrosis, resulting in heat ablation 
[2,37]. HIFU is a non-invasive method, as it does 
not require the percutaneous placement of probes 
into the pancreatic tumor [2,20].
HIFU has showed significant pain relief prop-
erties with studies demonstrating 67 to 100% of 
patients reporting pain relief, and with studies 
with more than 30 patients showing rates rang-
ing from 67 to 87% according to a recent system-
atic review [40] of 8 articles [41-48]. Significant 
reduction in tumor volume has also observed in 
multiple studies [41,42,44-50], with some studies 
showing complete initial response in all patients 
[51]. In his review of 14 articles using HIFU [6], 
Kean et al. reported median survival rates varying 
from 5.54 to 26 months in the largest study with 
89 patients [42], but most studies reported medi-
ans from 10 to 12.6 months [6] (Table 1).  
Mostly few and mild complications were ob-
served with usage of HIFU, the most common 
being subcutaneous sclerosis, second degree skin 
burn [42], mild pancreatitis [44], and pancreatic 
pseudocyst [42].  The most severe complication 
Table 2. Summary of articles reporting on median survival of non-thermal ablative techniques in unresectable 
pancreatic cancer
Article authors Publication year Ablative technique Number of patients Median survival (months)
Martin et al. [68] 2015 IRE 200 24.9 
Martin et al. [69] 2013 IRE 54 20.2
Narayanan. [71] 2012 IRE 14 6.7
Bown et al. [79] 2002 PDT 16 9.5 
For abbreviations see text
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reported was one case of portal vein thrombosis 
in a patient whose portal vein was compressed by 
the tumor with suspected further compression af-
ter HIFU by the edematous tumor; the patient was 
discharged after low-molecular-weight heparin 
treatment for one week [51]. 
Cryoablation
Cryoablation is a thermal method of ablation 
that uses very low temperatures to induce tumor 
ablation. This method works by the insertion of 
probes, known as “cryoprobes”, percutaneously 
into the tumor [2,20]. These probes can be placed 
percutaneously with CT guidance [52], or intra-
operatively with the use of ultrasound guidance 
[6]. The tumor is frozen to a temperature ranging 
from -40⁰C to -160⁰C, depending on the protocol, 
and then allowed to thaw back to 0⁰C [2,6,20,22]. 
This cycle of freezing and thawing is repeated at 
least twice and each cycle lasts from 3 to 5 min, 
again depending on the protocol [6,22]. Cryoabla-
tion leads to cell apoptosis and necrosis by means 
of direct cellular injury, vascular injury, and im-
munological injury [21,53].
Cryoablation, with and without adjuvant im-
munotherapy, has been shown in a 106-patient 
randomized control trial, to significantly increase 
patient survival when compared to standard 
chemotherapy [54]. The median survival was 7 
months with cryotherapy alone, 13 months with 
cryotherapy and adjuvant immunotherapy and 3.5 
months when a standard chemotherapy regimen 
was used (p<0.001) [54]. In a recent systematic 
review of 10 articles with various uses of cryo-
ablation [6], median survival was found to range 
from 7 to 14 months  when cryoablation was used 
alone, with both those studies having more than 
40 patients [54,55]. The highest median survival 
was found when cryoablation was used in con-
junction with palliative bypass surgery, with a 
median survival of 30.4 months [56] (Table 1).
Multiple minor complications have been re-
ported with mild abdominal pain being the most 
common in up to 76% of the patients [55], and 
the second most common being delayed gastric 
emptying reported in up to 40.9% of the patients 
[56-58]. Other complications included bleeding, 
pancreatic leak, bile leak, acute pancreatitis, and 
cryoprobe needle tract metastasis [55,57,59-61].
Non-thermal ablative methods
A wide range of non-thermal ablation tech-
niques are used as means of producing cell tis-
sue damage leading to necrosis. Chemicals, light, 
and electricity are examples of the energy types 
that can be used [2,6,20]. In this review, we cov-
er the use of electric energy through the use of 
irreversible electroporation, and the use of light 
energy through the use of photodynamic therapy. 
Chemical ablation as a form of non-thermal abla-
tion is not readily used in the pancreas due to the 
high fatality risk associated with using cytotoxic 
chemicals in such close proximity to major arter-
ies [2,19].
Irreversible electroporation (IRE)
IRE (NanoKnife®) is a promising novel abla-
tive method that uses brief and intense electric 
pulses that irreversibly disrupt cellular homeo-
stasis by forming nanoscale pores that destroy the 
integrity of the cellular membrane. This process 
ultimately leads to apoptosis of the tumor cells 
[6,62,63]. A cytotoxic immune response may also 
be responsible for the ablative capabilities of IRE 
[62]. The electric pulses are applied through the 
placement of electrodes inside the tumor which 
deliver direct current [6]. The probes can be placed 
percutaneously with the use of imaging guidance 
or under direct vision during open operations [62]. 
One of the greatest benefits of this novel tech-
nique is its safety towards adjacent non-cancer-
ous tissues. It is the only technique that has been 
shown to be safe to implement in tumors that are 
found in close proximity to vasculature, without 
causing vascular trauma [6,62]. IRE selectively 
causes only intracellular damage without harm-
ing the extracellular matrix, further increasing 
its relative safety compared to the other ablative 
methods [64-67]. 
New mortality data generated regarding pa-
tients, following an open IRE in addition to stand-
ard chemotherapy, is suggestive of a 24.9 months 
median survival, in a 200-patient study [68], the 
initial results showing a 20.2 months median sur-
vival two years prior [69] (Table 2). IRE has also 
been used for surgical margin accentuation [70] 
and control of local recurrence following a Whip-
ple procedure [71]. These uses have no reliable 
mortality data, although they are generally con-
sidered having a better prognosis than standard 
therapy [70,71]. 
Although generally considered safe [2,68-71], 
complications of this procedure include duodenal 
leaks [70] and pancreatitis, [71]. A contraindica-
tion to IRE would be the presence of a metallic 
bile stent, which could lead to perforation of the 
duodenum and colon, as well as bleeding and 
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death [72].
Photodynamic therapy (PDT)
PDT is an ablative method that utilizes the in-
teraction of light and tumor localizing photosen-
sitizing agents to induce an apoptotic response in 
malignant cells in a predictable zone of ablation 
[6,73]. This process is referred to as photo-killing 
and results in the irreversible photo-damage to tu-
mor tissues [73]. Photosensitizers are administered 
intravenously. Multiple photosensitizers are availa-
ble for PDT ablation including meso-tetra (hydroxy-
phenyl)chlorin (mTHPC), porfimer sodium, and 
verteporfin [6]. Light, in the form of laser light, is 
brought to the tumor site by fiber optic wires placed 
percutaneously with the help of image guidance 
[6,20]. Different photosensitizers have multiple cel-
lular and molecular targets that can be damaged 
to activate tumor cell apoptosis [73]. One well de-
scribed target of PDT is mitochondria [74,75] where 
some tumors resistant to PDT treatment have been 
found to have mitochondrial alterations [76]. An-
other target is tubulin found in the cytosol [77], uti-
lized to attack tumor cells rich in tubulin as a result 
of their higher rates of mitosis [78].
Mortality for post-PDT patients was only 
reported in a single 16-patient study to be 9.5 
months [79] (Table 2).
With the limited evidence available, only few 
complications were reported, one of which was 
significant gastrointestinal bleeding [79]. All pa-
tients had abdominal pain manageable with opi-
oids after the procedure for the first few days [79].
Discussion
Studies on these ablative therapies suggest 
that they are relatively safe and contribute to a 
rapid improvement of the clinical picture of unre-
sectable pancreatic adenocarcinoma. Thermal ab-
lative methods appear to provide significant im-
provement in mortality and symptom control, but 
they seem to carry higher risk of complications 
than non-thermal methods. RFA and MWA are 
quite accessible and relatively cheap. These two 
methods could see a rapid spread worldwide and 
could become part of the standard management 
with further improvements and research. HIFU, 
not requiring laparotomy or percutaneous needle 
placement, could also be indicated in a patient in 
whom surgery is not recommended. Non thermal 
ablative methods, although more expensive, show 
great promise. With less and milder complica-
tions, IRE appears to be the most promising meth-
od in our days. Further randomized controlled 
trials comparing different ablative methods with 
standard regimen would provide clearer data of 
their relative indications, efficacy and safety.
Conclusions
Ablative therapies for unresectable pancreat-
ic cancer have come a long way since their early 
days. Recent data demonstrated that most of these 
techniques are feasible, reproducible and quite 
safe. RFA, HIFU and MWA seem to have a definite 
place in the local control of pancreatic adenocar-
cinoma. Cryoablation, IRE and PDT are promising 
modalities that still require some improvement 
and decrease in operating costs for wider use. The 
early results of ablative therapies showcase their 
clear advantages over standard management with 
or without adjuvant chemotherapy but IRE seems 
to be the most promising with lower complica-
tions and equivalent survival. These emerging 
techniques will require larger prospective rand-
omized studies demonstrating their efficacy and 
safety before becoming part of the standard man-
agement algorithm for locally advanced pancreat-
ic cancer.
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